Acetylcholine Sample Clauses

Acetylcholine. Acetylcholine chloride [Sigma] was dissolved in H2O at a stock concentration of 100 mM and was applied at a concentration of 20 µM, unless otherwise stated.
View Source
Acetylcholine. Acetylcholine is synthesized from choline and acetyl co-enzyme A by choline acetyltransferase. After depolarization of the presynaptic neuron, it is released in the synaptic cleft and binds to the postsynaptic receptors. To limit its action, acetylcholine is degraded by acetylcholinesterase in the synaptic cleft. The cholinergic system consists of the neurons using acetylcholine as neurotransmitter for transsynaptic communication. The highest density of these neurons is found in the basal forebrain (including the nucleus basalis of Meynert and the substantia innominata) and the brain stem, with a widespread projection to the cerebral cortex.10 Cholinergic neurons can also be found in the peripheral nervous system and are crucial for neuromuscular signal transduction. The autonomic nervous system also contains many cholinergic neurons, influencing for example heart rate, blood pressure and bowel movements. Acetylcholine exerts its action by binding to the postsynaptic receptors, divided in two subtypes. The muscarinic AChRs in the central nervous system (cns), especially the M1 subtype, are mainly located in the cerebral cortex, hippocampus, striatum, nucleus accumbens, dentate gyrus and brainstem and associated with memory, arousal and sleep.11–15 Nicotinic AChRs are mostly found in the cerebral cortex, thalamus, hippocampus, dentate gyrus and striatum and associated with memory.16,17 There are several possible pharmacological approaches for stimulating the cholinergic system to accomplish a potential procognitive effect. To increase the level of ACh in the synaptic cleft, the break-down can be diminished by cholinesterase inhibitors. Another option is to stimulate the postsynaptic neuron with a direct AChR agonist. With these principals in mind, several compounds were developed to influence the cholinergic system. In the second half of the eighties, several M1 AChR agonists were evaluated because of the high density of M1 AChRs in the hippocampus. In general, they had positive cognitive effects, but the cholinergic side effects overshadowed the benefits. This might have been due to a lack of selectivity leading to dominant peripheral cholinergic stimulation.18 This strategy was therefore soon abandoned. The other approach, inhibiting ACh breakdown appeared more hopeful and several cholinesterase inhibitors were developed.19–23 The cholinesterase inhibitor (cei) tacrine was the first to acquire registration in 1995. The registration was supported by mitiga...
View Source
Acetylcholine. Nicotinic
View Source
Acetylcholine. Lamina III is a projection site of Aβ and Aδ cutaneous afferents (▇▇▇▇▇▇ and ▇▇▇▇▇▇▇▇▇▇ 1991) and is the likely location of interneurons interposed in PAD of cutaneous afferents (Jankowska, ▇▇▇▇▇▇ et al. 1981).Intriguingly, it is also the predominant location of dorsal horn cholinergic interneurons (Olave, Puri et al. 2002) - well positioned to contribute to PAD (▇▇▇▇ 1991; ▇▇▇▇▇▇▇ 1998). Acetylcholine (ACh) and GABA co-exist in a population of dorsal horn interneurons (▇▇▇▇ 1991) and are found in ~25% of the synapses presynaptic to afferent axons (▇▇▇▇▇▇▇ 1998). Thus, there is ample anatomic evidence to support ACh as a transmitter contributing to PAD. Intriguingly, while the early literature did not identify acetylcholine (ACh) as a neurotransmitter in primary afferents (▇▇▇▇▇▇ and ▇▇▇▇▇▇▇▇▇▇ 1991), recent work strongly challenges these studies. First, an alternative splice variant of the ACh synthesis enzyme choline acetyltransferase (ChAT) has been identified. Peripheral ChAT (pChAT) is preferentially localized in peripheral neurons including in dorsal root ganglia (DRG) (Tooyama and Kimura 2000), and has sufficient enzyme activity in the adult rat DRG to produce physiological concentrations of Ach (Bellier and Kimura 2007). PChAT is expressed in both small and large diameter primary afferents (Bellier and Kimura 2007) and immunolabeling studies identify pChAT in myelinated primary afferents that project via dorsal columns to brainstem dorsal column nuclei (Yasuhara, Aimi et al. 2008). DRG neurons have also been shown to express the vesicular ACh transporter (VAChT) preferentially in large-diameter DRG neurons (Tata, De Stefano et al. 2004) as well as the ACh degradative enzyme acetylcholinesterase (AChE) (▇▇▇▇▇▇ and ▇▇▇▇▇▇▇▇▇▇ 1991; Bellier and Kimura 2007). Widespread ChAT labeling in DRG was also observed in mice, including ChAT-GFP BAC transgenic mice (▇▇▇▇▇▇▇, ▇▇▇▇ et al. 2006), and treatment with antisense oligonucleotides reduced labeling (Matsumoto, Xie et al. 2007).
View Source

Related to Acetylcholine

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • Influenza Vaccine Upon recommendation of the Medical Officer of Health, all employees shall be required, on an annual basis to be vaccinated and or to take antiviral medication for influenza. If the costs of such medication are not covered by some other sources, the Employer will pay the cost for such medication. If the employee fails to take the required medication, she may be placed on an unpaid leave of absence during any influenza outbreak in the home until such time as the employee has been cleared by the public health or the Employer to return to the work environment. The only exception to this would be employees for whom taking the medication will result in the employee being physically ill to the extent that she cannot attend work. Upon written direction from the employee’s physician of such medical condition in consultation with the Employer’s physician, (if requested), the employee will be permitted to access their sick bank, if any, during any outbreak period. If there is a dispute between the physicians, the employee will be placed on unpaid leave. If the employee gets sick as a reaction to the drug and applies for WSIB the Employer will not oppose the application. If an employee is pregnant and her physician believes the pregnancy could be in jeopardy as a result of the influenza inoculation and/or the antiviral medication she shall be eligible for sick leave in circumstances where she is not allowed to attend at work as a result of an outbreak. This clause shall be interpreted in a manner consistent with the Ontario Human Rights Code.

  • Therapies Acupuncture and acupuncturist services, including x-ray and laboratory services. • Biofeedback, biofeedback training, and biofeedback by any other modality for any condition. • Recreational therapy services and programs, including wilderness programs. • Services provided in any covered program that are recreational therapy services, including wilderness programs, educational services, complimentary services, non- medical self-care, self-help programs, or non-clinical services. Examples include, but are not limited to, Tai Chi, yoga, personal training, meditation. • Computer/internet/social media based services and/or programs. • Recreational therapy. • Aqua therapy unless provided by a physical therapist. • Maintenance therapy services unless it is a habilitative service that helps a person keep, learn or improve skills and functioning for daily living. • Aromatherapy. • Hippotherapy. • Massage therapy rendered by a massage therapist. • Therapies, procedures, and services for the purpose of relieving stress. • Physical, occupational, speech, or respiratory therapy provided in your home, unless through a home care program. • Pelvic floor electrical and magnetic stimulation, and pelvic floor exercises. • Educational classes and services for speech impairments that are self-correcting. • Speech therapy services related to food aversion or texture disorders. • Exercise therapy. • Naturopathic, homeopathic, and Christian Science services, regardless of who orders or provides the services. • Eye exercises and visual training services. • Lenses and/or frames and contact lenses for members aged nineteen (19) and older. • Vision hardware purchased from a non-network provider. • Non-collection vision hardware. • Lenses and/or frames and contact lenses unless specifically listed as a covered healthcare service.

  • Vlastnictví Zdravotnické zařízení si ponechá a bude uchovávat Zdravotní záznamy. Zdravotnické zařízení a Zkoušející převedou na Zadavatele veškerá svá práva, nároky a tituly, včetně práv duševního vlastnictví k Důvěrným informacím (ve smyslu níže uvedeném) a k jakýmkoli jiným Studijním datům a údajům.

  • Speech Therapy This plan covers speech therapy services when provided by a qualified licensed • loss of speech or communication function; or • impairment as a result of an acute illness or injury, or an acute exacerbation of a chronic disease. Speech therapy services must relate to: • performing basic functional communication; or • assessing or treating swallowing dysfunction. See Autism Services when speech therapy services are rendered as part of the treatment of autism spectrum disorder. The amount you pay and any benefit limit will be the same whether the services are provided for habilitative or rehabilitative purposes.